180 related articles for article (PubMed ID: 21604273)
1. Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Mayordomo C; García-Recio S; Ametller E; Fernández-Nogueira P; Pastor-Arroyo EM; Vinyals L; Casas I; Gascón P; Almendro V
J Cell Physiol; 2012 Apr; 227(4):1358-66. PubMed ID: 21604273
[TBL] [Abstract][Full Text] [Related]
2. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.
Garcia-Recio S; Fuster G; Fernandez-Nogueira P; Pastor-Arroyo EM; Park SY; Mayordomo C; Ametller E; Mancino M; Gonzalez-Farre X; Russnes HG; Engel P; Costamagna D; Fernandez PL; Gascón P; Almendro V
Cancer Res; 2013 Nov; 73(21):6424-34. PubMed ID: 24030979
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
4. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
7. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
8. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
9. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
10. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
12. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
13. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
14. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
Tomioka H; Mukohara T; Kataoka Y; Ekyalongo RC; Funakoshi Y; Imai Y; Kiyota N; Fujiwara Y; Minami H
Int J Oncol; 2012 Aug; 41(2):551-8. PubMed ID: 22614071
[TBL] [Abstract][Full Text] [Related]
17. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A
Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
